HRMY Valuation

Harmony Biosciences Holdings Inc

Add to Watchlist

Advanced Chart

31.430

+0.49(1.584%)1D

HRMY Relative Valuation

HRMY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, HRMY is overvalued; if below, it's undervalued.

Historical Valuation

Harmony Biosciences Holdings Inc (HRMY) is now in the Undervalued zone, suggesting that its current forward PE ratio of 8.28 is considered Undervalued compared with the five-year average of 19.38. The fair price of Harmony Biosciences Holdings Inc (HRMY) is between 38.62 to 113.66 according to relative valuation methord. Compared to the current price of 31.43 USD , Harmony Biosciences Holdings Inc is Undervalued By 18.62%.

Relative Value

Fair Zone

38.62-113.66

Current Price：31.43

18.62%

Undervalued

8.28

Trailing

Forward

4.56

EV/EBITDA

Harmony Biosciences Holdings Inc. (HRMY) has a current EV/EBITDA of 4.56. The 5-year average EV/EBITDA is 10.83. The thresholds are as follows: Strongly Undervalued below 0.23, Undervalued between 0.23 and 5.53, Fairly Valued between 16.13 and 5.53, Overvalued between 16.13 and 21.43, and Strongly Overvalued above 21.43. The current Forward EV/EBITDA of 4.56 falls within the Undervalued range.

4.67

EV/EBIT

Harmony Biosciences Holdings Inc. (HRMY) has a current EV/EBIT of 4.67. The 5-year average EV/EBIT is 12.76. The thresholds are as follows: Strongly Undervalued below -0.98, Undervalued between -0.98 and 5.89, Fairly Valued between 19.63 and 5.89, Overvalued between 19.63 and 26.50, and Strongly Overvalued above 26.50. The current Forward EV/EBIT of 4.67 falls within the Undervalued range.

31.43

Harmony Biosciences Holdings Inc. (HRMY) has a current PS of 31.43. The 5-year average PS is 4.39. The thresholds are as follows: Strongly Undervalued below -1.57, Undervalued between -1.57 and 1.41, Fairly Valued between 7.37 and 1.41, Overvalued between 7.37 and 10.35, and Strongly Overvalued above 10.35. The current Forward PS of 31.43 falls within the Strongly Overvalued range.

5.50

P/OCF

Harmony Biosciences Holdings Inc. (HRMY) has a current P/OCF of 5.50. The 5-year average P/OCF is 13.24. The thresholds are as follows: Strongly Undervalued below -3.20, Undervalued between -3.20 and 5.02, Fairly Valued between 21.46 and 5.02, Overvalued between 21.46 and 29.69, and Strongly Overvalued above 29.69. The current Forward P/OCF of 5.50 falls within the Historic Trend Line -Fairly Valued range.

6.95

P/FCF

Harmony Biosciences Holdings Inc. (HRMY) has a current P/FCF of 6.95. The 5-year average P/FCF is 12.67. The thresholds are as follows: Strongly Undervalued below 3.27, Undervalued between 3.27 and 7.97, Fairly Valued between 17.37 and 7.97, Overvalued between 17.37 and 22.07, and Strongly Overvalued above 22.07. The current Forward P/FCF of 6.95 falls within the Undervalued range.

Harmony Biosciences Holdings Inc (HRMY) has a current Price-to-Book (P/B) ratio of 2.17. Compared to its 3-year average P/B ratio of 4.04 , the current P/B ratio is approximately -46.32% higher. Relative to its 5-year average P/B ratio of 8.52, the current P/B ratio is about -74.56% higher. Harmony Biosciences Holdings Inc (HRMY) has a Forward Free Cash Flow (FCF) yield of approximately 0.16%. Compared to its 3-year average FCF yield of 10.26%, the current FCF yield is approximately -98.40% lower. Relative to its 5-year average FCF yield of 7.25% , the current FCF yield is about -97.74% lower.

2.17

P/B

Median3y

4.04

Median5y

8.52

0.16

FCF Yield

Median3y

10.26

Median5y

7.25

Competitors Valuation Multiple

The average P/S ratio for HRMY's competitors is 23.21, providing a benchmark for relative valuation. Harmony Biosciences Holdings Inc Corp (HRMY) exhibits a P/S ratio of 31.43, which is 35.40% above the industry average. Given its robust revenue growth of 28.71%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

HRMY.O

Harmony Biosciences Holdings Inc

Phibro Animal Health Corp

Maze Therapeutics Inc

Performance Decomposition

Market capitalization of HRMY decreased by 9.35% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 186.04M to 239.46M.

The secondary factor is the Margin Expansion, contributed -14.29%to the performance.

Overall, the performance of HRMY in the past 1 year is driven by Revenue Growth. Which is more sustainable.

28.71%

186.04M → 239.46M

Revenue Growth

-14.29%

24.78 → 21.24

Margin Expansion

-23.77%

13.02 → 9.92

P/E Change

-9.35%